Company Encyclopedia
View More
name
Cormedix
CRMD.US
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc.
4.514 T
CRMD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking27/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE75.08%A
    • Profit Margin75.83%A
    • Gross Margin92.74%A
  • Growth ScoreA
    • Revenue YoY1647.67%A
    • Net Profit YoY452.12%A
    • Total Assets YoY867.78%A
    • Net Assets YoY537.23%A
  • Cash ScoreB
    • Cash Flow Margin131.88%C
    • OCF YoY1647.67%A
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreC
    • Gearing Ratio50.17%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dir Dillione Sells 46,657 ($466.6K) Of CorMedix Inc [CRMD]

    Janet Dillione, Director of CorMedix Inc, disclosed a Form 4 filing with the SEC, revealing the sale of 46,657 shares at $10.00 each, totaling $466,570. The transaction was part of a prearranged trading plan (10b5-1). Dillione also exercised 46,657 shares at $3.96 each, valued at $184,804, with ending holdings of 48,473 shares.

    Reuters·
    US
    CRMD
    +3.10%
    Reuters·
    US
    CRMD
    +3.10%

    CorMedix Director Janet Dillione Sells 26,343 Shares

    Reporter NameDillione JanetRelationshipDirector, 10% OwnerTypeSellAmount$261,585SEC FilingForm 4Janet Dillione, a 10% owner and director of CorMedix, sold 26,343 shares of common stock on November 24, 2025, at a weighted average price of $9.93 per share, totaling $261,585. Following the transaction, Dillione directly owns 48,473 shares of CorMedix.SEC Filing: CorMedix Inc. [ CRMD ] - Form 4 - Nov. 26, 2025

    TradingView·
    US
    CRMD
    +3.10%
    TradingView·
    US
    CRMD
    +3.10%

    Dir Dillione Sells 26,343 ($261.6K) Of CorMedix Inc [CRMD]

    Janet Dillione, Director of CorMedix Inc, filed a Form 4 with the SEC on November 26, 2025, disclosing the sale of 26,343 shares at $9.93 each, totaling $261,586. The shares were exercised at $3.64 each. Ending holdings are 48,473 shares. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    CRMD
    +3.10%
    Reuters·
    US
    CRMD
    +3.10%

    Dir Dillione Files To Sell 73,000 Of CorMedix Inc [CRMD]

    Dillione Janet, Director of CorMedix Inc, filed a Form 144 with the SEC to sell 73,000 restricted shares on November 24, 2025, through Merrill Lynch & Co Inc, under a prearranged trading plan (10b5-1). This filing allows the sale within 90 days.

    Reuters·
    US
    CRMD
    +3.10%
    Reuters·
    US
    CRMD
    +3.10%

    Dir Dillione Sells 30,000 ($342.6K) Of CorMedix Inc [CRMD]

    Dillione Janet Director of CorMedix Inc [CRMD] filed a Form 4 on November 18, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/14/25TransactionSaleShares30,000Price$11.42Value$342,600Ending Holdings: 48,473 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    CRMD
    +3.10%
    Reuters·
    US
    CRMD
    +3.10%
    © 2025 Longbridge｜Disclaimer